Therapy with interferon and ribavirin for hepatitis C virus (HCV) infection induces a decrease in several haematological population counts. It is unclear whether haematological toxicity is more severe in patients co-infected with HCV and human immunodeficiency virus (HIV). This study analysed the evolution of haematological population counts during and after interferon and ribavirin therapy for chronic HCV infection. Eleven patients co-infected with HIV and HCV and treated with pegylated interferon plus ribavirin, and ten treated with standard interferon plus ribavirin, were analysed. With reference to baseline values, neutrophil counts decreased by an average of 45% (range 18-67%), total lymphocytes by 50% (16-63%), CD4 lymphocytes by 54% (16-61%), haemoglobin by 9% (5-16%) and platelets by 31% (16-45%). The nadir of the decrease was reached in the first weeks of therapy and was maintained while patients were receiving treatment. The reduction in all series was higher with pegylated interferon. Patients recovered their baseline counts after finishing the treatment. No cases of haemorrhage or outstanding infection were detected during follow-up.
The increase in the survival of human immunodeficiency virus (HIV)-infected patients, related to highly active anti-retroviral therapy (HAART) [1] , has been associated with higher morbidity and mortality attributed to chronic hepatitis C virus (HCV) infection [2] . HCV-induced liver disease shows an accelerated course in patients co-infected with HIV [3] [4] [5] [6] . Treatment of HCV infection with interferon-a (IFN-a) and ribavirin can lead to sustained eradication of the virus, which is associated with a long-term improvement in liver histology and, probably, with a reduction in the risk of cirrhosis [7, 8] .
Treatment with IFN and ribavirin is not without shortcomings. A common side-effect is bone marrow suppression [9] . With the doses of IFN required to treat hepatitis C, neutrophil and lymphocyte counts can fall to levels associated with an increase in the risk of opportunistic infections [10] . This potential fall was not usually associated with infection in a recent series of non-HIV-infected patients receiving therapy against HCV-related chronic hepatitis [11] . However, although studies are currently underway, the risk in HIV-co-infected patients has not yet been evaluated properly [12] [13] [14] [15] [16] . Moreover, the combination with ribavirin, apart from increasing the risk of anaemia, can reinforce the neutropenia produced by IFN [7] [8] [9] [10] 17] .
In order to evaluate the haematological toxicities of IFN (both pegylated and standard) plus ribavirin in the treatment of chronic HCV infection in HIV-co-infected patients, the present study analysed prospectively the evolution of the different haematological populations during and after this therapy, as well as the incidence of opportunistic infections and haemorrhagic complications.
P A T I E N T S A N D M E T H O D S Study population
This was a prospective study of 21 patients in the Hospital Universitario Puerta del Mar (Cadiz, Spain) who were co-infected with HIV and HCV. This tertiary hospital serves a population of 270 000 inhabitants. The cumulative prevalence of AIDS in this area is 570 ⁄ million inhabitants. Patients were selected from those individuals who attended the Infectious Disease Unit. Inclusion criteria were: [19] , was the indication for therapy. Exclusion criteria were as follows: (1) clinical or biochemical criteria of decompensated cirrhosis; (2) positive hepatitis B surface antigen; (3) other infectious, autoimmune, tumoural, biliary or vascular-associated liver disease; (4) active alcohol or drug dependence; (5) a Karnofsky index of < 80; (6) absolute neutrophil counts of < 1500 cells ⁄ lL, a platelet count of < 90 000 cells ⁄ lL or a haemoglobin concentration of < 11.0 g ⁄ dL; (7) poorly controlled psychiatric disease; (8) substantial coexisting medical conditions; (9) inability to use contraceptive measures, for any reason; and (10) previous IFN or ribavirin therapy.
The study protocol was approved by the Institutional Ethical Committee, and all patients and controls gave their informed consent.
Study design
Eleven patients were selected at random to receive treatment with pegylated IFN-a-2a (PEG-IFN, Pegasys; Hoffman-La Roche, Nutley, NJ, USA) at a dose of 180 lg subcutaneously each week, plus ribavirin. Another ten patients received treatment with IFN-a-2a (standard IFN) (Roferon-A; Hoff-man-La Roche) at a dose of 3 million units three times weekly, plus ribavirin. The daily dose of ribavirin for patients in both groups was 800 mg. Treatment was continued for 48 weeks.
All patients were followed in a similar way, with a visit for selection during the 35 days before the start of treatment. At this initial visit, a detailed clinical history was taken, with haematogram and differential counts, coagulation and routine biochemical tests, thyrotropin and anti-thyroid antibody measurements, an elemental study of urine, thorax radiography, abdominal ultrasonography, and determination of HCV genotype, HCV and HIV virus loads, and CD4 + T-cell counts. Once the patient had been selected, clinical and analytical evaluations were performed in weeks 0, 2, 4, 6, 8, 12, 24, 48 and 72. In each of these evaluations, the results of anamnesis and physical examination, complete blood counts, CD4 + T-cell counts, and routine liver and renal tests, were recorded. Determinations of HIV RNA and HCV RNA load were performed at 4, 12, 24, 48 and 72 weeks.
Side-effects and toxicity of therapy were classified according to the usual criteria [20] . Dose adjustments following changes in neutrophil, haemoglobin and platelet counts are reported in Table 1 . Colony-stimulating factors were not administered. Co-trimoxazole prophylaxis was given to patients with < 200 CD4 + T-cells ⁄ lL during the follow-up.
Criteria for interruption of the study were: (1) appearance of an opportunistic infection; (2) concurrent disease that required the use of immunosuppressive therapy; (3) virological failure in the control of HIV infection; (4) decision of the patient not to continue the treatment; or (5) positive HCV RNA after treatment for 24 weeks in those patients who received standard IFN plus ribavirin.
Laboratory determinations
Automated tests were used for the haematogram, routine biochemistry, coagulation and the elemental study of urine.
Serum reactivity for anti-HIV was determined by enzyme immunoassay (EIA; Abbott Laboratories, North Chicago, IL, USA) and confirmed with Western blot (Pasteur Institute, Paris, France). CD4 cell counts were determined by standard flow cytofluorometry. Plasma HIV load was determined by RT-PCR (Amplicor HIV; Roche Diagnostics, Basel, Switzerland), with a sensitivity of 50 RNA copies ⁄ mL of plasma.
Sera from all subjects were reactive for anti-HCV by both a second-generation EIA (EIA-2; Ortho Diagnostic System, Raritan, NJ, USA) and a second-generation recombinant immunoblot assay (RIBA-2; Ortho Diagnostic System). Plasma samples were tested for HCV RNA by RT-PCR (Amplicor HCV; Roche Diagnostics). When values exceeded the range of the assay, plasma samples were diluted and determinations were repeated. HCV genotypes were determined by line probe assay (INNO-LiPA HCV; Innogenetics, Antwerp, Belgium) as described previously [21] .
Graduation of necroinflammatory activity and the fibrosis stage of liver biopsies was performed with the index of histological activity proposed by Knodell, modified by Desmet et al. [19] .
Statistical analysis
Quantitative variables are presented as means ± standard deviations if they followed a normal distribution, according to the Shapiro-Wilk test, or as median values with 95% confidence intervals (95% CI). Qualitative variables are presented as absolute numbers and percentages. Data from two independent groups were compared with the Mann-Whitney U-test. The significance of parameters within each group was tested with the Wilcoxon matched-pairs signedrank test. For qualitative variables, the chi-square test with Yates' correction or Fisher's exact test was used. A p value of < 0.05 was considered significant. Statistical analyses were performed with SSPS v.11.0 software (SPSS Inc., Chicago, IL, USA).
R E S U L T S
Twenty-one patients were included in the treatment protocol. The baseline characteristics of individuals are shown in Table 2 . There was no significant difference between the standard IFN and PEG-IFN groups with respect to baseline demographics, or histological or virological characteristics. Likewise, anti-retroviral therapy was similar in both groups (data not shown).
A maintained virus response (negative for HCV RNA at 6 months after completion of therapy) was observed for nine (42.9%) patients, of whom seven were in the PEG-IFN group and two were in the standard IFN group. Twelve (57.1%) patients remained positive for HCV RNA. Of these, five patients receiving standard IFN had a detectable RNA virus load at week 24; treatment was withdrawn from these patients. Two further patients receiving PEG-IFN had a detectable virus load at 48 weeks, and a third patient, with a virological response at 48 weeks, subsequently relapsed, with HCV RNA being detectable at 72 weeks. Therapy was suspended for the final five patients because of adverse effects: one cirrhotic patient in the standard IFN group had a hydropic decompensation in week 8; a patient in the PEG-IFN group presented with hyperthyroidism in week 20; and the final two patients, one from each treatment group, suffered a depressionanxiety disorder, and asked for therapy to be suspended (both in week 18). Quantitative variables are expressed as medians (interquartile range). Data correspond to the time when liver biopsy was performed.
Changes in blood cell and platelet counts and haemoglobin concentration during therapy
Baseline counts for neutrophils, total and CD4 + lymphocytes, and platelets, as well as haemoglobin concentrations, are shown in Table 3 . The values of these parameters were similar (p > 0.05 in every case) in patients given PEG-IFN and in those given standard IFN. In both groups of patients, an early and maintained decrease in all of the haematological series was observed ( Table 4 ). The largest decrease in neutrophil counts was reached after therapy for 2 weeks with standard IFN, and after 4 weeks in patients receiving PEG-IFN. Two patients with neutrophil counts of < 750 cells ⁄ mL needed an adjustment of their IFN dose (Table 1 ). Fig. 1 shows the changes in white cell and platelet counts and haemoglobin concentrations over time. As the secondary effects resulting in discontinuation of therapy presented at later stages, data from the patients who discontinued therapy are included. The lowest lymphocyte count occurred at week 8 in patients receiving standard IFN, and at week 12 in patients treated with PEG-IFN. The lowest CD4 lymphocyte count occurred at week 24 in patients receiving standard IFN, and at week 12 in patients treated with PEG-IFN; however, the percentage of CD4 + T-cells in relation to the total lymphocyte count was maintained during the entire follow-up period. Six patients presented with CD4 + T-cell values of < 200 ⁄ mL; prophylaxis with co-trimoxazole was initiated in these patients.
Platelet counts also diminished in the patients studied. Those in the PEG-IFN group showed larger and earlier decreases (week 4 of therapy) than those in the standard IFN group (time until nadir was 12 weeks). In three patients, the dose of IFN was reduced following a platelet count of < 50 000 cells ⁄ mm 3 (Table 1) .
A slight decrease in haemoglobin concentrations was also detected, with the lowest value being reached at 12 weeks in the PEG-IFN group and at 18 weeks in the standard IFN group. Haemolytic anaemia was searched for and discounted in all of the patients.
The dosages of PEG-IFN, standard IFN and ribavirin were not related to the patients' body weights. A correlation of weight with the magnitude of the decrease in every item in the haematological series was performed, but there were no statistically significant correlations. Likewise, in none of the haematological series was the decrease associated with the presence or absence of response to IFN plus ribavirin therapy (data not shown).
Patients were placed into two function groups according to whether their baseline values were higher or lower than the median value of each series. The percentage decrease was independent of the baseline count (data not shown). Every patient receiving PEG-IFN showed a decrease in all levels analysed, with the exception of the platelet count in two patients, which remained stable. In the group of patients receiving standard IFN therapy (n = 10), eight showed a decrease in neutrophil count, seven in the total lymphocyte count, nine in the CD4 lymphocyte count, nine in the platelet count, and seven in the haemoglobin concentration. Additionally, a larger median decrease was observed in patients receiving PEG-IFN in comparison with those receiving standard IFN (Table 4) .
Changes at follow-up
Twenty-four weeks after completing treatment, either by premature retirement (virological failure, adverse effects) or by completion of therapy for patients with virological response, patients were re-evaluated. At this visit, median haematological values had returned to their baseline levels (Fig. 1) . However, two patients still had a CD4 T-cell count of < 200 ⁄ lL; both were in the PEG-IFN group. None of the patients developed a haemorrhagic complication or an opportunistic infection during the follow-up. Likewise, the HIV viral load remained undetectable in those patients where it was undetectable at baseline, and remained at similar levels (p > 0.05) in the remaining patients.
D I S C U S S I O N
This study analysed the dynamics of haematological changes in HIV-infected patients receiving treatment for chronic HCV infection. It was evident from the data that all parameters in the haematological series decreased during treatment with IFN and ribavirin. IFN is a bone marrow depressor that inhibits the effects of several haematopoietic growth factors. It inhibits production of stimulating cytokines, such as granulocyte and granulocyte-macrophage colony-stimulating factor, interleukin-1, interleukin-8 and interleukin-11, and it increases the concentrations of inhibitors (antagonistic receptor of interleukin-1) [22, 23] , with all the haematopoietic series being affected in different forms and degrees [24] . This suppression effect is dose-dependent [9, 17] . The combination with ribavirin increases the risk of anaemia and, probably, the risk of neutropenia [7, 8, 17] . The effect on CD4 + T-cell counts has not been explained clearly, although the reduction in numbers of this lymphocyte subset has been linked to a redistribution [25] .
Descriptive analyses of haematological toxicities have been performed in HCV-mono-infected patients being treated for chronic hepatitis. A reduction in white blood cell counts is the most frequent haematological toxicity observed in patients treated with IFN [7, 8] . Fortunately, this reduction in neutrophils has not been associated with an increased risk of bacterial infection [11] . Indeed, in a pooled analysis of 2089 patients in the pivotal studies of combination therapy for hepatitis C [26] [27] [28] , neutropenia was not associated with infection, with only one of 23 deaths reported from these studies being caused by infection.
An association between drug-induced neutropenia and infection has been shown in chemotherapy studies, such as with oncology patients undergoing therapy that severely suppresses the immune system and bone marrow [29] . HIVinfected patients have a high predisposition to infectious diseases, mainly associated with a lower CD4 + T-cell count. Thus, IFN-induced decreases in neutrophil and lymphocyte counts could be of greater relevance in this kind of patient [30] . Consequently, therapy with IFN is prescribed currently for HIV-infected patients with a relatively intact immune system [17, 31, 32] . The present data show that a 45% decrease in neutrophil counts occurs in these patients. This decrease implies the possibility of severe neutropenia (< 750 cells ⁄ mm 3 ) in patients who begin treatment with < 1500 neutrophils ⁄ mm 3 , and the IFN doses were adjusted because of low neutrophil counts in two patients in the present series. However, as has been demonstrated for non-HIV-infected patients [11, [21] [22] [23] , these lower values were not associated with an increase in severe bacterial infections (those indicating hospital admission). Likewise, an increase in opportunistic infections related to a lower CD4 + T-cell count was not observed in these patients. This is a remarkable situation because, although a preserved CD4 + T-cell count was present in this series of patients at the beginning of the treatment, the magnitude of the decrease in CD4 lymphocyte count (a median decrease of 54%) could contribute to immunosuppression. Thrombocytopenia was also relatively common in patients of this series, but no severe haemorrhagic complications were detected. Finally, the smallest reduction in the haematological series was observed in haemoglobin concentration. Evolution of red blood series is of concern in HIV-infected patients because of the influence in vitro of several nucleoside inhibitors of reverse transcriptase on ribavirin concentrations [33, 34] . This was not a problem in the present series, with haemoglobin values of > 10 g ⁄ dL being found during the entire followup period in every patient.
One of the most interesting findings of this work was the analysis of the dynamics of the haematological series. The nadir was detected at an early stage (2-4 weeks in the case of neutrophils, and up to 18 weeks in the case of lymphocytes). Remarkably, the reduction in haematological cell counts persisted during the entire course of treatment. Previously, a rebound in the levels of the blood populations during the course of therapy has been reported [25] . This was not the case in the present series, although the curve for lymphocytes (total and CD4) was complex ( Fig. 1) , because two separate curves were superimposed, namely the curve for patients treated with PEG-IFN, where a continued decrease in lymphocyte numbers during therapy was demonstrated, and the curve for patients treated with standard IFN, where a rebound can be seen after the first few weeks of therapy. Recent results from a controlled trial of therapy with PEG-IFN plus ribavirin in patients co-infected with HIV and HCV also support the maintenance of a decrease in the CD4 + T-cell count during therapy [35] .
Diminution seems to be a common phenomenon in patients treated with PEG-IFN: all the cases receiving PEG-IFN in this study had significant reductions in neutrophil and lymphocyte counts and in haemoglobin concentration; in nine of 11 patients, a significant and concomitant diminution of platelet count was observed. Additionally, the decrease in patients receiving PEG-IFN plus ribavirin was greater than that detected in patients receiving standard IFN combined with ribavirin. With a more extended use of PEG-IFN, frequent dose adjustments may be required to avoid these haematological toxicities. However, a reduction in the amount of drug administered has been linked with reduced effectiveness [36] . Alternatively, colony-stimulating factors, not investigated in this study, could be used to allow the full doses of IFN and ribavirin to be administered without severe haematological toxicity.
Although no patients had severe opportunistic infections or haemorrhagic complications during this study (that is, the decrease in neutrophil and lymphocyte counts could be interpreted as not being excessively favourable to opportunistic infections in HIV-infected patients treated with IFN and ribavirin), caution must be exercised because of the low number of patients. Studies with larger patient series, currently under way, will be needed to explore this topic.
